Q4 2020 13F Holders as of 31 Dec 2020
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
104,661,494
-
Number of holders
-
150
-
Total 13F shares, excl. options
-
52,750,406
-
Shares change
-
+3,363,781
-
Total reported value, excl. options
-
$1,494,882,254
-
Value change
-
+$97,410,291
-
Put/Call ratio
-
264%
-
Number of buys
-
73
-
Number of sells
-
-71
-
Price
-
$28.34
Significant Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) as of Q4 2020
188 filings reported holding RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q4 2020.
Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) has 150 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 52,750,406 shares
of 104,661,494 outstanding shares and own 50% of the company stock.
Largest 10 shareholders include BlackRock Inc. (5,012,352 shares), JPMORGAN CHASE & CO (4,326,053 shares), Essex Woodlands Management, Inc. (3,342,047 shares), WELLINGTON MANAGEMENT GROUP LLP (3,268,117 shares), VANGUARD GROUP INC (3,240,171 shares), ALLIANCEBERNSTEIN L.P. (3,065,904 shares), ArrowMark Colorado Holdings LLC (2,964,135 shares), FMR LLC (2,852,000 shares), Palo Alto Investors LP (2,673,313 shares), and JENNISON ASSOCIATES LLC (2,201,508 shares).
This table shows the top 150 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.